Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Identification of Isavuconazole Exposure–Toxicity Threshold in Invasive Mold Disease
ChiCTR2600126942Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of isavuconazole in Invasive mold disease (IMD), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Plasma concentration of isavuconazole, Isavuconazole exposure–toxicity threshold and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
isavuconazole
03
Conditions
Invasive mold disease (IMD)
Beyond the preview
Go deeper on ChiCTR2600126942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126942.